Subcutaneous Immunoglobulins: Product Characteristics and Their Role in Primary Immunodeficiency Disease

REFERENCES

• Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol 2007;27:497–502.
   PubMed Web of Science ®Google Scholar
• Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther Clin Risk Manag 2010;6:1–10.
   PubMed Web of Science ®Google Scholar
• Bruton OC. Agammaglobulinemia. Pediatrics 1952;9:722–728.
   PubMed Web of Science ®Google Scholar
• Berger M. A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies. Curr Allergy Asthma Rep 2002;2:368–738.
   PubMedGoogle Scholar
• Berger M, Cupps TR, Fauci AS. Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann Intern Med 1980;93:55–56.
   PubMed Web of Science ®Google Scholar
• Misbah S, Sturzenegger MH, Borte M, Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol 2009;158(Suppl 1):51–59.
   PubMedGoogle Scholar
• Gardulf A, Hammarstrom L, Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991;338:162–166.
   PubMed Web of Science ®Google Scholar
• Hansen S, Gustafson R, Smith CI, Gardulf A. Express subcutaneous IgG infusions: decreased time of delivery with maintained safety. Clin Immunol 2001;104:237–241.
   Google Scholar
• Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am 2008;28:413–437.
   PubMed Web of Science ®Google Scholar
• Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs 2007;21:105–116.
   PubMed Web of Science ®Google Scholar
• Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol 2010;30:301–307.
   PubMed Web of Science ®Google Scholar
• Chapel HM, Spickett GP, Ericson D, The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000;20:94–100.
   PubMed Web of Science ®Google Scholar
• Abrahamsen TG, Sandersen H, Bustnes A. Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics 1996;98:1127–1131.
   PubMed Web of Science ®Google Scholar
• Dams ET, van der Meer JW. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies. Lancet 1995;345:864.
   Web of Science ®Google Scholar
• Gardulf A, Andersen V, Bjorkander J, Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995;345:365–369.
   PubMed Web of Science ®Google Scholar
• Gardulf A, Bjorvell H, Gustafson R, The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clin Exp Immunol 1993;92:200–204.
   PubMed Web of Science ®Google Scholar
• Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child 1998;79:48–51.
   PubMed Web of Science ®Google Scholar
• Grunebaum E, Levy Y, Shoenfeld Y. Novel aspects of hypogammaglobulinemic states: subcutaneous immunoglobulin treatment. Isr Med Assoc J 2002;4:288–289.
   Google Scholar
• Thomas MJ, Brennan VM, Chapel HH. Rapid subcutaneous immunoglobulin infusions in children. Lancet 342:1432–1433.
   Google Scholar
• Weiler CR. Immunoglobulin therapy: history, indications, and routes of administration. Int J Dermatol 2004;43:163–166.
   PubMed Web of Science ®Google Scholar
• Sundin U, Nava S, Hammarstrom L. Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol 1998;112: 341–346.
   PubMed Web of Science ®Google Scholar
• Gardulf A, Bjorvell H, Gustafson R, Safety of rapid subcutaneous gammaglobulin infusions in patients with primary antibody deficiency. Immunodeficiency 1993;4:81–84.
   PubMedGoogle Scholar
• Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am 2008;28:803–819.
   PubMed Web of Science ®Google Scholar
• Berger M, Murphy E, Riley P, Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J 2010;103(9):856–863.
   PubMed Web of Science ®Google Scholar
• Berger M. Subcutaneous IgG therapy in immune deficiency diseases. In: Blaese RM, editor. Clinical focus on primary immune deficiencies. Towson, MD: Immune Deficiency Foundation; February 2008:1–12. http://primaryimmune.org/about-primary-immunodeficiency-diseases/publications. Accessed 1/11/2012.
   Google Scholar
• Orange JS, Hossny EM, Weiler CR, Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117:S525–S553.
   PubMed Web of Science ®Google Scholar
• Gardulf A, Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol 2006;6:434–442.
   PubMed Web of Science ®Google Scholar
• Ochs HD, Gupta S, Kiessling P, Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006;26:265–273.
   PubMed Web of Science ®Google Scholar
• Gustafson R, Gardulf A, Hansen S, Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies. Clin Exp Immunol 2008;152:274–279.
   PubMed Web of Science ®Google Scholar
• Waniewski J, Gardulf A, Hammarstrom L. Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol 1994;14:90–97.
   PubMedGoogle Scholar
• Gardulf A, Nicolay U, Math D, Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004;114(4):936–942.
   PubMed Web of Science ®Google Scholar
• Gammagard liquid [immune globulin infusion (human)] 10% prescribing information. Westlake Village, CA: Baxter Healthcare Corporation, 2012.
   Google Scholar
• Gamunex-C (immune globulin injection [human] 10% caprylate/chromatography purified) prescribing information. Research Triangle Park, NC: Talecris Biotherapeutics, Inc., 2010.
   Google Scholar
• Hizentra immune globulin subcutaneous (human) (IGSC), 20% liquid prescribing information. Kankakee, IL: CSL Behring LLC, 2011.
   Google Scholar
• Vivaglobin immune globulin subcutaneous (human) 16% liquid prescribing information. Kankakee, IL: CSL Behring LLC, 2010.
   Google Scholar
• Gammagard S/D [immune globulin intravenous (human)], solvent detergent treated, IgA less than 2.2 μg/mL in a 5% solution. Westlake Village, CA: Baxter Healthcare Corporation, December 2009.
   Google Scholar
• Immune Deficiency Foundation. Characteristics of immune globulin products currently licensed for use in the United States. http://primaryimmune.org/treatment-information/immunoglobulin-products. Accessed October 2012.
   Google Scholar
• Wasserman RL, Melamed I, Kobrynski L, Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol 2011;31:323–331.
   PubMed Web of Science ®Google Scholar
• Wasserman RL, Irani AM, Tracy J, Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease. Clin Exp Immunol 2010;161:518–526.
   PubMed Web of Science ®Google Scholar
• Borte M, Ritchie B, Plebani A, Improvement in quality of life measurements in newly diagnosed patients with primary immunodeficiency receiving directly initiated subcutaneous replacement therapy with Vivaglobin. Abstract # 551. J Allergy Clin Immunol 2010;125:AB140.
   Google Scholar
• Schiff RI, Williams LW, Nelson RP, Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases. J Clin Immunol 1997;17:21–28.
   PubMed Web of Science ®Google Scholar
• Melamed I, Neff A, McDonald A. Subcutaneous immunoglobulins (IGSC): product characteristics and their role in primary immunodeficiency disease (PIDD). Paper presented at the Clinical Immunology Society Meeting, 12–22 May 2011; Chicago, IL, Poster presentation # 29.
   Google Scholar
• Berger M. Choices of IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and optimal dose. Curr Opin allergy Clin Immunol 2011;11:32–538.
   Google Scholar
• Stein MR, Koterba A, Rodden, Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases. Postgrad Med 2011;123(5):186–193.
   PubMed Web of Science ®Google Scholar
• Kaveri SV, Maddur MS, Hegde P, Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol 2011;164(Suppl 2):2–5.
   PubMed Web of Science ®Google Scholar
• Durandy A, Kaveri SV, Kuijpers TW, Intravenous immunoglobulins –understanding properties and mechanisms. Clin Exp Immunol 2009;158(Suppl 1):2–13.
   PubMed Web of Science ®Google Scholar